期刊文献+
共找到983篇文章
< 1 2 50 >
每页显示 20 50 100
Research Progress on the Mechanism of Correlation Between Vitamin D and Thyroid Cancer
1
作者 Xiaojuan Ran 《Journal of Clinical and Nursing Research》 2024年第8期105-111,共7页
Vitamin D is a kind of fat-soluble vitamin,which is mainly involved in the metabolism of calcium and bone in the human body.As a metabolic substance,it also has a certain impact on the cellular microenvironment,and vi... Vitamin D is a kind of fat-soluble vitamin,which is mainly involved in the metabolism of calcium and bone in the human body.As a metabolic substance,it also has a certain impact on the cellular microenvironment,and vitamin D also inhibits the proliferation of tumor cells.25(OH)D is considered the best index to evaluate the vitamin D level in the human body because of its relatively stable characteristics in the circulation.Thyroid cancer is a common malignant tumor that develops from malignant thyroid nodules.A large number of studies have found that the lower the serum 25(OH)D level,the higher the risk of thyroid nodules.A large number of studies have found that the lower the serum 25(OH)D level,the higher the risk of thyroid nodules. 展开更多
关键词 thyroid cancer Vitamin D Wnt/β-catenin signaling pathway EGFR gene polymorphism
下载PDF
Gene Expression of Fas,Soluble Fas and Fas-Ligand in Thyroid Tissues and Thyrocytes from Patients with Graves′ Disease 被引量:1
2
作者 武晓泓 刘超 +3 位作者 覃又文 刘翠萍 段宇 蒋须勤 《Journal of Nanjing Medical University》 2002年第1期12-17,共6页
ObjectiveTo investigate Fas,soluble Fas(sFas)and Fas ligand(Fas L)gene expression in thyroid tissues and thyrocytes from patients with Graves disease(GD)and to find the interrelationship between apoptosis and pathog... ObjectiveTo investigate Fas,soluble Fas(sFas)and Fas ligand(Fas L)gene expression in thyroid tissues and thyrocytes from patients with Graves disease(GD)and to find the interrelationship between apoptosis and pathogenesis of GD. MethodsThyroid tissues were obtained from 7 GD patients and 3 healthy subjects who died accidentally. Thyrocytes were cultured in Eagle′s medium. Total RNA was isolated from thyroid tissues and cultured thyrocytes. The cDNA was prepared by reverse transcription and amplified for Fas,sFas and Fas L by polymerase chain reaction(PCR). ResultsFas and sFas mRNA were detected in all samples from both GD and normal thyroid tissues and thyrocytes,but Fas L mRNA was only found in GD thyroid tissues and thyrocytes. Semi quantitative analysis showed that when compared with those of normal controls,the Fas and sFas mRNA levels were markedly increased in GD thyroid tissues(P<0.01),whereas in GD thyrocytes only the sFas mRNA levels was significantly elevated(P<0.01). ConclusionGene expression of Fas,sFas and Fas L showed abnormality in both thyroid tissues and thyrocytes from GD. The increased production of sFas might be involved in the hyperplasia of thyroid gland. 展开更多
关键词 thyroid Graves′ disease apoptosis Fas/Fas L gene expression
下载PDF
TSH RECEPTOR GENETIC ALTERATIONS IN THE AUTONOMOUSLY FUNCTIONING THYROID ADENOMAS
3
作者 施秉银 李雪萍 +3 位作者 李社莉 薛明战 王毅 徐莉 《Journal of Pharmaceutical Analysis》 SCIE CAS 2004年第1期39-41,共3页
Objective To determine the relationship between TSH receptor gene mutations and autonomously functioning thyroid adenomas (AFTAs). Methods The thyroid samples from 14 cases of diagnosed AFTAs were analyzed, with nor... Objective To determine the relationship between TSH receptor gene mutations and autonomously functioning thyroid adenomas (AFTAs). Methods The thyroid samples from 14 cases of diagnosed AFTAs were analyzed, with normal thyroid specimens adjacent to the tumors as controls. The 155 base pairs DNA fragments which encompassed the third cytoplasmic loop and the sixth transmembrane segments in the TSH receptor gene exon 10 were amplified by Polymerase chain reaction (PCR) and analyzed by the single-strand conformation polymorphism (SSCP). Direct sequencing of the PCR products was performed with Prism Dye Terminator Cycle Sequencing Core Kit. Results 6 of 14 AFTA specimens displayed abnormal migration in SSCP analysis. In sequence analysis of 3 abnormally migrated samples, one base substitution at nucleotide 1957 (A to C) and two same insertion mutations of one adenosine nucleotide between nucleotide 1972 and 1973 were identified. No mutations were found in controls. Conclusion This study confirmed the presence of TSH receptor gene mutations in AFTAs; both one-point substitution mutation and one-base insertion mutation were found to be responsible for the pathogenesis of AFTAs. 展开更多
关键词 thyrotropin receptor autonomously functioning thyroid adenoma gene mutation
下载PDF
Genetic Background May Confer Susceptibility to PTC in Benign Multinodular Thyroid Disease
4
作者 Sivatharsiny Thavarajah Frank Weber 《Journal of Cancer Therapy》 2012年第6期997-1001,共5页
Purpose: The incidence of hyperplastic thyroid nodular disease has been consistently rising over the last decades. In addition, unsuspected papillary thyroid carcinoma (PTC) can be found in up to 34% of patients opera... Purpose: The incidence of hyperplastic thyroid nodular disease has been consistently rising over the last decades. In addition, unsuspected papillary thyroid carcinoma (PTC) can be found in up to 34% of patients operated for benign thyroid lesions. PTC tends to occur multi-focally and is commonly of polyclonal origin. We set out to test the hypothesis that in benign thyroid disease, a unique genetic signature can already be identified in the benign pathology, which is associated with a susceptibility of the thyroid tissue to neoplastic transformation in the context of additional growth promoting stimuli. Patients and Methods: We obtained a set of 23 samples from patients with multinodular goiter (MNG), 12 of whom also harbored an unsuspected PTC. We used global gene expression analysis to evaluate for dissimilarities in the gene expression patterns between these two groups. We also compared these patterns to the profiles of 3 normal thyroid and 7 PTC samples. Results: We were able to accurately distinguish between hyperplastic nodules of patients with multinodular goiter and those that were associated with a PTC. One of the strongest differentially expressed genes, CDC42, has been implicated to respond to environmental factors such as UVB radiation and might point to novel factors contributing to PTC genesis in the setting of pre-existing benign proliferative disease. Conclusion: While the comparison between histologically identical samples cannot distinguish the two groups of goiters, unsupervised or supervised approaches allowed us to identify a molecular signature associated with PTC susceptibility in multinodular goiter. 展开更多
关键词 Multinodular GOITER Cancer Suceptibility gene Expression PAPILLARY thyroid Carcinoma
下载PDF
Autoimmune Thyroid Disease Genes Identified in Non-Caucasians
5
作者 Yoshihisa Ban Yoshiyuki Ban Yoshio Ban 《Open Journal of Endocrine and Metabolic Diseases》 2012年第4期107-116,共10页
Autoimmune thyroid diseases (AITDs), including Graves’ disease (GD) and Hashimoto’s thyroiditis (HT), are among the commonest autoimmune disorders, affecting approximately 2% - 5% of the population. Epidemiological ... Autoimmune thyroid diseases (AITDs), including Graves’ disease (GD) and Hashimoto’s thyroiditis (HT), are among the commonest autoimmune disorders, affecting approximately 2% - 5% of the population. Epidemiological data support strong genetic influences on the development of AITD. The identification of genes placing individuals at an increased risk for the development of AITD has been a slow process. However, over the last 20 years or so real progress has been made with the mapping of novel loci, via a number of different approaches. The first AITD gene discovered, Human Leucocyte Antigen (HLA)/Major Histocompatibility Complex (MHC), is associated with both GD and HT. Non-MHC genes that confer susceptibility to AITD can be classified into two groups: (1) immune-regulatory genes (e.g., CD40, CTLA-4, and PTPN22);(2) thyroid-specific genes—thyroglobulin and TSH receptor genes. These genes interact with environmental factors, such as infection, likely through epigenetic mechanisms to trigger disease. In this review, we will summarize the latest findings on AITD susceptibility genes in non-Caucasians. 展开更多
关键词 gene thyroid AUTOIMMUNITY ASSOCIATION
下载PDF
Identifying Driver Genes Mutations with Clinical Significance in Thyroid Cancer
6
作者 Hyeong Won Yu Muhammad Afzal +4 位作者 Maqbool Hussain Hyungju Kwon Young Joo Park June Young Choi Kyu Eun Lee 《Computers, Materials & Continua》 SCIE EI 2021年第4期1241-1251,共11页
Advances in technology are enabling gene mutations in papillary thyroid carcinoma(PTC)to be analyzed and clinical outcomes,such as recurrence,to be predicted.To date,the most common genetic mutation in PTC is in BRAF ... Advances in technology are enabling gene mutations in papillary thyroid carcinoma(PTC)to be analyzed and clinical outcomes,such as recurrence,to be predicted.To date,the most common genetic mutation in PTC is in BRAF kinase(BRAF).However,whether mutations in other genes coincide with those in BRAF remains to be clarified.The aim of this study was to find mutations in other genes that co-exist with mutated BRAF,and to analyze their frequency and clinical relevance in PTC.Clinical and genetic data were collected from 213 PTC patients with a total of 36,572 mutation sites in 735 genes.After matching with genes from PTC entries in a global database(NCBI Gene),69 genes with mutations in coding regions were chosen for further study.Through frequency-based analysis,we identified commonly mutated genes co-existing with mutated BRAF and,using the mutation count correlation matrix(MCCM)method,analyzed their incidence according to age and gender.We designed Chord diagrams to reveal gene relationships concerning age and gender,and found that mutations in ALK,ATM,COL1A1,MSTIR,PRKCA,and WNK1 most commonly coincide with mutated BRAF,followed by APC,AURKA,and AURKB.These findings provide further insight into the genetic profile of PTC. 展开更多
关键词 Medical informatics papillary thyroid carcinoma CANCER gene mutation analysis BRAF clinical significance
下载PDF
Screening and bioinformatics analysis of thyroid cancer-related hub genes
7
作者 Shu-Fei Wu Shuang Yang +3 位作者 Jiu Pu Zheng-Hai Ling Zheng-Wei Leng Ling-Mi Hou 《TMR Clinical Research》 2020年第3期109-116,共8页
Objective:To identify the thyroid cancer-related hub genes and pathways by bioinformatics initially in order to lay the foundation for further study.Methods:The expression profile chips and data of thyroid cancer were... Objective:To identify the thyroid cancer-related hub genes and pathways by bioinformatics initially in order to lay the foundation for further study.Methods:The expression profile chips and data of thyroid cancer were screened and downloaded from the gene expression omnibus(GEO).The GEO2R was applied to identify the differential expressed genes between thyroid cancer tissues and normal thyroid tissues.And the Metascape online website was used for pathway and function enrichment.With the usage of STRING and Cytoscape,the protein-protein interaction network was constructed,and the plug-in app cytoHubba in Cytoscape was applied to screen hub genes.Kaplan-Meier Plotter was implemented to conduct survival analysis of hub genes for further screening and discussion.Results:A total of 304 differential expressed genes were screened,and were mainly enriched in the biological processes of extracellular matrix,cell-substrate adhesion,response to wounding,muscle structure development and hormone metabolic process etc.by Metascape.Protein-protein interaction network visualized 284 nodes;the top ten scores of Maximal Clique Centrality algorithm were taken as the criteria to screen out the hub genes with high connectivity in the gene expression network.The KM plotter analysis confirmed that 5 of 9 hub genes were correlated with the prognosis of thyroid cancer patients.Conclusion:FN1,SPP1,TIMP1,VCAN,COL1A1,COL1A2,MMP1,DCN,COMP and FMOD may play a significant role in the development of thyroid cancer.Genes which have prognostic significance in survival analyses were found to be relevant to the composition and regulation of extracellular matrix. 展开更多
关键词 BIOINFORMATICS thyroid cancer Hub genes Differential expressed genes
下载PDF
Evaluation of autophagy-related genes and lncRNAs signature for prognositic prediction in thyroid carcinoma via bioinformatics analysis
8
作者 Shan-Qi Guo Ying-lie lia +1 位作者 Deng Hao xiao-jiang Li 《TMR Clinical Research》 2021年第2期25-41,共17页
Autophagy plays a significant role in the pathogenesis and prognosis of thyroid carcinoma.The role of autophagy-related genes and long non-coding RNAs,as well as the risk model of thyroid carcinoma patients were inves... Autophagy plays a significant role in the pathogenesis and prognosis of thyroid carcinoma.The role of autophagy-related genes and long non-coding RNAs,as well as the risk model of thyroid carcinoma patients were investigated to predict clinical outcome of thyroid carcinoma.Different expression of autophagy-related genes and long non-coding RNAs in thyroid carcinoma patients was identified in The Cancer Genome Atlas database.Functional enrichment analysis and gene set enrichment analysis was used to hint the mechanism that autophagy might act in thyroid carcinoma.Univariate and multivariate Cox regression analyses were performed for screening the prognostic autophagy-related genes and long non-coding RNAs to construct prognostic related risk model.thyroid carcinoma patients were divided into the low-risk and high-risk groups.The overall survival time was both shorter in the high-risk groups than that in the low-risk groups.As for autophagy-related genes prognostic risk model,age and autophagy-related genes risk score are independent prognostic factors that affect the survival of thyroid carcinoma.ATIC and CDKN2A expression was closely related to pathological stage and T status,DNAJB1 expression was closely related to M status,age and gender.While autophagy-associated long non-coding RNA related prognostic risk model consequently demonstrated that the long non-coding RNA risk score could significantly predict the survival rate of thyroid carcinoma patients with areas under the curve of 0.972.gene set enrichment analysis presented that a total of 16 gene sets including 10 up-regulated and 6 down-regulated gene sets were significantly enriched.The autophagy-related genes and long non-coding RNAs based prognostic risk models are a reliable forecasting tool for thyroid carcinoma patients. 展开更多
关键词 Autophagy-related gene Long non-coding RNA PROGNOSIS thyroid carcinoma The Cancer Genome Atlas
下载PDF
远处转移性甲状腺乳头状癌生化进展的影响因素研究
9
作者 彰金 孙迪 +6 位作者 王昊 石聪 赵翊含 潘逸缙 慕转转 丁治国 林岩松 《中国全科医学》 CAS 北大核心 2024年第36期4546-4553,共8页
背景晚期甲状腺乳头状癌(PTC),尤其是远处转移性甲状腺乳头状癌(DM-PTC)的病情变化主要从甲状腺球蛋白(Tg)等血清学指标和CT等影像学两方面进行监测。由于CT等影像学手段本身的局限性如辐射、价格昂贵及转移病灶分布的复杂性,实体瘤疗... 背景晚期甲状腺乳头状癌(PTC),尤其是远处转移性甲状腺乳头状癌(DM-PTC)的病情变化主要从甲状腺球蛋白(Tg)等血清学指标和CT等影像学两方面进行监测。由于CT等影像学手段本身的局限性如辐射、价格昂贵及转移病灶分布的复杂性,实体瘤疗效评估标准(RECIST 1.1)常无法及时捕捉DM-PTC患者的病情变化,而整合了时间维度的Tg倍增时间(TgDT)已显示其在灵敏监测PTC疾病变化中的作用。目的以TgDT为结局变量,探索DM-PTC的生化进展及其影响因素。方法回顾性纳入2018年1月—2023年6月北京协和医院核医学科就诊的61例DM-PTC患者为研究对象,通过门诊病历系统收集研究对象的基线资料并进行基因突变检测,基因突变检测内容包括鼠类肉瘤滤过性毒菌致癌同源体B1(BRAF)突变、端粒酶反转录酶(TERT)突变、转染重排(RET)融合、大鼠肉瘤病毒(RAS)突变。末次^(131)I治疗后4个月到1年时间内行外周血T细胞亚群、自然杀伤细胞(NK细胞)及淋巴细胞检测。计算TgDT,以TgDT 3年为界,将研究对象分为<3年组(n=16)和≥3年组(n=45)。末次^(131)I治疗后4个月到1年时间内,计算TgDT的初次Tg时间点的T细胞亚群、NK细胞百分比及淋巴细胞绝对值被定义为淋巴细胞亚群的初始值,计算TgDT的末次Tg时间点的T细胞亚群、NK细胞百分比及淋巴细胞绝对值被定义为淋巴细胞亚群的末次值,淋巴细胞亚群随时间纵向变化情况以淋巴细胞亚群变化率表示,淋巴细胞亚群变化率=(末次值-初始值)/初始值×100%。比较两组淋巴细胞亚群初始值及变化率的差异情况。采用多因素Logistic逐步向后回归分析探究DM-PTC生化进展的影响因素。结果≥3年组确诊年龄、末次^(131)I治疗前局部手术次数、碘难治(RAIR)、TERT突变、BRAF与TERT共同突变比例低于<3年组,RET融合比例高于<3年组(P<0.05)。≥3年组CD_(3)^(+)T细胞百分比、CD_(8)^(+)T细胞百分比高于<3年组,NK细胞百分比、CD4/CD8低于<3年组(P<0.05)。多因素Logistic回归分析结果显示CD_(8)^(+)T细胞百分比降低(OR=0.879,95%CI=0.792~0.975)、BRAF与TERT共同突变(OR=7.044,95%CI=1.368~36.265)是DM-PTC生化进展的影响因素(P<0.05)。结论低CD_(8)^(+)T细胞比例的免疫状态、BRAF与TERT共同突变等多种因素可影响DM-PTC的生化进展,淋巴细胞亚群及多基因联合检测对于DM-PTC病情监测及预后评价具有重要意义。 展开更多
关键词 甲状腺乳头状癌 远处转移 生化进展 甲状腺球蛋白倍增时间 T淋巴细胞亚群 基因突变
下载PDF
甲状腺弥漫性大B细胞淋巴瘤临床病理特征、基因突变谱及预后分析 被引量:1
10
作者 杜沚珊 王玥 +7 位作者 石子旸 施晴 易红梅 董磊 王黎 程澍 许彭鹏 赵维莅 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2024年第1期64-71,共8页
目的·探究甲状腺弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)临床病理特征、基因突变谱及预后相关因素。方法·回顾性分析2003年11月—2021年12月上海交通大学医学院附属瑞金医院收治的66例初次诊断为甲状腺DL... 目的·探究甲状腺弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)临床病理特征、基因突变谱及预后相关因素。方法·回顾性分析2003年11月—2021年12月上海交通大学医学院附属瑞金医院收治的66例初次诊断为甲状腺DLBCL患者[原发甲状腺DLBCL 23例(34.8%),继发甲状腺DLBCL 43例(65.2%)]的临床病理资料,并进行生存和预后因素分析。其中40例甲状腺DLBCL患者进行了靶向测序(55个淋巴瘤相关基因)以评估基因突变情况。结果·继发甲状腺DLBCL患者Ann Arbor分期Ⅲ~Ⅳ期(P=0.000)、乳酸脱氢酶(lactate dehydrogenase,LDH)升高(P=0.043)、结外器官受累数目≥2个(P=0.000)、非生发中心来源(non-GCB)(P=0.030)、MYC和BCL2蛋白双表达(double expression,DE)(P=0.026)、国际预后指数3~5分(P=0.000)的比例高于原发甲状腺DLBCL患者,其接受甲状腺手术切除的比例(P=0.012)低于原发甲状腺DLBCL患者。原发甲状腺DLBCL患者完全缓解(complete response,CR)率高于继发患者(P=0.039)。55例患者(83%)接受以利妥昔单克隆抗体联合环磷酰胺、阿霉素、长春新碱及泼尼松(R-CHOP)为基础的一线治疗方案,其中原发甲状腺DLBCL患者预期5年无进展生存(progress free survive,PFS)率95.0%,高于继发患者的49.7%(P=0.010)。单因素分析显示:Ann ArborⅢ~Ⅳ期(HR=4.411,95%CI 1.373~14.170)、LDH升高(HR=5.500,95%CI 1.519~19.911)、non-GCB(HR=5.291,95%CI 1.667~16.788)、DE(HR=6.178,95%CI 1.813~21.058)是甲状腺DLBCL患者PFS的不良预后因素;Ann ArborⅢ~Ⅳ期(HR=7.088,95%CI 0.827~60.717)、LDH升高(HR=6.982,95%CI 0.809~60.266)、DE(HR=18.079,95%CI 1.837~177.923)是总生存(overall survival,OS)时间的不良预后因素。多因素分析显示:Ann ArborⅢ~Ⅳ期(HR=4.693,95%CI 1.218~18.081)和LDH升高(HR=5.058,95%CI 1.166~21.941)是甲状腺DLBCL患者PFS的独立不良预后因素。靶向测序结果显示,TET2(n=14,35%)、KMT2D(n=13,32%)、TP53(n=11,28%)、GNA13(n=10,25%)、KMT2C(n=9,22%)突变频率>20%,且TP53突变是甲状腺DLBCL患者PFS的不良预后因素(P=0.000)。结论·原发甲状腺DLBCL生存情况优于继发甲状腺DLBCL。Ann ArborⅢ~Ⅳ期、LDH升高、non-GCB、DE(MYC和BCL2)是影响甲状腺DLBCL患者的不良预后因素。TET2、KMT2D、TP53、GNA13、KMT2C是甲状腺DLBCL中常见的高突变基因,TP53突变的患者预后不佳。 展开更多
关键词 甲状腺 弥漫性大B细胞淋巴瘤 临床病理特征 基因突变谱 预后分析
下载PDF
血清HbA1c、LAG-3与2型糖尿病患者合并甲状腺结节的相关性 被引量:1
11
作者 杨晓月 宋红红 +3 位作者 胡少珍 潘颖 鲍晓雪 闫文英 《国际检验医学杂志》 CAS 2024年第2期160-164,共5页
目的探究血清糖化血红蛋白(HbA1c)、淋巴细胞活化基因-3(LAG-3)与2型糖尿病(T2DM)患者合并甲状腺结节的相关性。方法纳入河北医科大学第三医院2021年7月至2022年7月收治的T2DM合并甲状腺结节患者120例,设为研究组;同期选取单纯T2DM患者... 目的探究血清糖化血红蛋白(HbA1c)、淋巴细胞活化基因-3(LAG-3)与2型糖尿病(T2DM)患者合并甲状腺结节的相关性。方法纳入河北医科大学第三医院2021年7月至2022年7月收治的T2DM合并甲状腺结节患者120例,设为研究组;同期选取单纯T2DM患者(无甲状腺结节)100例作为对照组。根据甲状腺结节的病理学检查结果将研究组分为良性结节组(85例)和恶性结节组(35例)。采用酶联免疫吸附试验检测所有研究对象血清LAG-3水平;全自动糖化血红蛋白分析仪检测所有研究对象HbA1c水平。采用Spearman法分析T2DM合并甲状腺结节患者血清中HbA1c、LAG-3与甲状腺影像报告与数据系统(TI-RADS)评分的相关性。采用多因素Logistic回归分析T2DM合并甲状腺结节的影响因素。采用受试者工作特征(ROC)曲线分析HbA1c、LAG-3水平对T2DM合并甲状腺结节的诊断价值。结果与对照组比较,研究组HbA1c水平升高(P<0.05),LAG-3水平降低(P<0.05)。与良性结节组比较,恶性结节组血清中LAG-3水平降低(P<0.05),HbA1c水平升高(P<0.05)。Spearman法分析结果显示,T2DM合并甲状腺结节患者HbA1c水平与TI-RADS评分呈正相关(r=0.378,P<0.001);血清LAG-3水平与TI-RADS评分呈负相关(r=-0.472,P<0.001)。多因素Logistic回归分析结果显示,HbA1c是T2DM患者发生甲状腺结节的危险因素(P<0.05),LAG-3是T2DM患者发生甲状腺结节的保护因素(P<0.05)。HbA1c、LAG-3联合诊断T2DM合并甲状腺结节优于二者单独诊断(Z二者联合-HbA1c=2.542,P=0.011;Z二者联合-LAG-3=3.098,P=0.002)。结论T2DM合并甲状腺结节患者血清LAG-3水平明显降低,HbA1c水平明显升高,二者与甲状腺结节的恶性程度有关。 展开更多
关键词 糖化血红蛋白 淋巴细胞活化基因-3 糖尿病 甲状腺结节
下载PDF
甲状腺癌分子标志物及其在临床诊疗中的应用进展
12
作者 滕伟强 王秋阳 +4 位作者 马毅 张才云 郑宏良 朱乘婧 刘济生 《海军军医大学学报》 CAS CSCD 北大核心 2024年第9期1127-1133,共7页
甲状腺癌发病与环境因素密切相关,环境变化导致的基因突变和腺体组织分子生物学改变是诱发甲状腺癌的重要因素之一。尽管甲状腺癌的相关分子机制仍未完全阐明,但随着分子生物学技术的发展,越来越多的甲状腺癌特定遗传改变和分子标志物... 甲状腺癌发病与环境因素密切相关,环境变化导致的基因突变和腺体组织分子生物学改变是诱发甲状腺癌的重要因素之一。尽管甲状腺癌的相关分子机制仍未完全阐明,但随着分子生物学技术的发展,越来越多的甲状腺癌特定遗传改变和分子标志物被挖掘出来。本文就甲状腺癌的病因、特异性分子标志物、诊断及靶向治疗研究进展进行综述,为甲状腺癌的临床诊疗提供理论支持。 展开更多
关键词 甲状腺肿瘤 分子机制 分子标志物 癌基因 基因突变 基因重排
下载PDF
超声特征与甲状腺乳头状癌基因突变及病理亚型的相关性
13
作者 李惠霖 张波 《中国医学科学院学报》 CAS CSCD 北大核心 2024年第5期747-755,共9页
甲状腺乳头状癌(PTC)的基因突变和病理亚型与其预后密切相关。PTC常见的基因突变包括BRAF V600E突变、RET/PTC重排和RAS突变,既往研究证明,PTC的基因突变与其复发风险增加、术后放射性碘治疗效果变差、生存期降低等有关。PTC病理亚型包... 甲状腺乳头状癌(PTC)的基因突变和病理亚型与其预后密切相关。PTC常见的基因突变包括BRAF V600E突变、RET/PTC重排和RAS突变,既往研究证明,PTC的基因突变与其复发风险增加、术后放射性碘治疗效果变差、生存期降低等有关。PTC病理亚型包括经典型、滤泡型、高细胞型、柱状细胞型、靴钉型、弥漫硬化型、固体/小梁型、嗜酸细胞型、沃辛瘤样型、透明细胞型、梭形细胞型等,其侵袭性和临床预后各不相同,因此检测PTC基因突变和鉴别病理亚型,对治疗方案的选择和预后评估有着极其重要的意义。超声具有无创、便捷和分辨率高等诸多优势,是甲状腺癌诊疗的重要影像检查方法。本文回顾了PTC基因突变和病理亚型与超声表现的相关研究,以期在术前运用超声影像预测PTC基因突变和病理亚型,为PTC术前精准评估预后提供新思路。 展开更多
关键词 甲状腺乳头状癌 超声 基因突变 病理亚型
下载PDF
甲状腺乳头状癌临床、多模态超声及病理学特征与BRAF V600E突变的相关性
14
作者 孙鑫 张巍 +2 位作者 程令刚 广旸 张雨康 《中国医学影像技术》 CSCD 北大核心 2024年第5期730-734,共5页
目的观察甲状腺乳头状癌(PTC)临床、多模态超声及病理学特征与BRAF V600E突变的相关性。方法前瞻性收集临床疑诊甲状腺恶性病变患者,获取病理学及基因检测结果后,根据BRAF V600E基因检测结果将PTC分为BRAF V600E突变(+)(突变组)和BRAF V... 目的观察甲状腺乳头状癌(PTC)临床、多模态超声及病理学特征与BRAF V600E突变的相关性。方法前瞻性收集临床疑诊甲状腺恶性病变患者,获取病理学及基因检测结果后,根据BRAF V600E基因检测结果将PTC分为BRAF V600E突变(+)(突变组)和BRAF V600E突变(-)(野生型组);以单因素分析及多因素logistic回归分析组间临床、常规超声、超声造影(CEUS)及病理学表现,筛选PTC BRAF V600E基因突变的独立预测因素。结果共纳入116例PTC患者(116个病灶),包括突变组77例、野生型组39例。组间甲状腺过氧化物酶抗体(TPO-Ab)水平,常规超声所示病灶大小、方位、边缘、微钙化,CEUS显示增强后病灶大小变化、平均通过时间(MTT),以及病理学显示被膜外侵犯、颈部中央区淋巴结转移及合并良性结节占比差异均有统计学意义(P均<0.05);其中,TPO-Ab、多模态超声所示病灶方位及增强后病灶大小变化、病理学颈部中央区淋巴结转移均为PTC BRAF V600E基因突变的独立预测因素(OR=0.175、3.868、5.769、6.943,P均<0.05)。结论患者TPO-Ab水平,多模态超声所示病灶方位、增强后病灶大小变化及病理学显示颈部中央区淋巴结转移均与PTC BRAF V600E基因突变独立相关。 展开更多
关键词 乳头状 甲状腺肿瘤 超声检查 BRAF V600E基因 前瞻性研究
下载PDF
二代测序技术检测442例甲状腺乳头状癌基因突变及其临床病理学特征
15
作者 施栋梁 姚梅宏 +4 位作者 吴丹 黄达妮 陈醉 郑宇辉 杨映红 《诊断病理学杂志》 2024年第2期135-139,共5页
目的探讨甲状腺乳头状癌(PTC)基因改变及其与临床病理学特征的关系。方法通过二代测序技术对442例PTC患者进行基因检测,同时收集患者的临床病理学资料。结果(1)442例PTC患者中,423例患者检出基因突变,其中BRAF(385例)、RET(24例)、KRAS(... 目的探讨甲状腺乳头状癌(PTC)基因改变及其与临床病理学特征的关系。方法通过二代测序技术对442例PTC患者进行基因检测,同时收集患者的临床病理学资料。结果(1)442例PTC患者中,423例患者检出基因突变,其中BRAF(385例)、RET(24例)、KRAS(5例)、NTRK3(3例)、NTRK1(3例);(2)BRAF基因突变仅与肿瘤最大径相关(P=0.006);(3)V600E突变丰度与性别、肿瘤最大径、肿瘤单/双侧、腺外侵犯、淋巴结转移、组织学亚型(P均<0.05)相关;(4)V600E不同突变丰度与肿瘤最大径、癌灶分布、腺外侵犯、淋巴结转移、组织学亚型(P均<0.05)相关。结论应用NGS技术可以明确PTC各驱动基因变异的独特特征,此外BRAF基因V600E突变与多项高危的临床病理学特征相关。 展开更多
关键词 甲状腺乳头状癌 二代测序 基因突变 BRAF
下载PDF
细针穿刺活检联合高通量测序技术在甲状腺结节诊疗中的应用
16
作者 朱枫 李青 +2 位作者 陈曦 贺洋 彭蕾 《实用医学杂志》 CAS 北大核心 2024年第17期2471-2476,共6页
目的 探讨甲状腺细针穿刺细胞学检查联合高通量测序18基因检测在甲状腺结节诊疗中的作用及其临床意义。方法 回顾性研究2021年7—12月苏州大学附属第三医院病理科接收的甲状腺细针穿刺标本97例,送检标本同时行液基细胞学及高通量测序18... 目的 探讨甲状腺细针穿刺细胞学检查联合高通量测序18基因检测在甲状腺结节诊疗中的作用及其临床意义。方法 回顾性研究2021年7—12月苏州大学附属第三医院病理科接收的甲状腺细针穿刺标本97例,送检标本同时行液基细胞学及高通量测序18基因检测,其中33例获得术后病理结果。细胞学诊断依据第3版甲状腺细胞病理Bethesda报告分类标准。组织学诊断依据第5版WHO甲状腺肿瘤分类标准。结果 97例甲状腺细针穿刺标本中标本不满意8例(8.25%),良性病变44例(45.36%),意义不明确的不典型病变9例(9.28%),可疑滤泡性肿瘤或嗜酸细胞肿瘤4例(4.12%),可疑乳头状癌10例(10.31%),乳头状癌22例(22.68%)。共有52例(53.61%)检出突变,共检出点突变及基因融合突变10个,其中BRAF突变检出率最高,达63.46%(33/52),BRAF突变在性别、年龄及细胞学诊断各组间差异均有统计学意义(P <0.05)。细胞学检查联合高通量测序基因检测诊断的准确性为97.0%,高于单纯细胞学检查(81.8%),具有更高的诊断效能。结论 甲状腺细针穿刺细胞学检查联合高通量测序多基因检测可以促进对甲状腺癌的早期诊断,也可为患者的个体化精准治疗提供参考。 展开更多
关键词 细针穿刺细胞学检查 高通量测序 基因突变 甲状腺癌
下载PDF
超声影像组学及联合基因检测筛选高侵袭性甲状腺乳头状癌研究进展
17
作者 马梦娇 王娴 钱晓芹 《中国医学影像技术》 CSCD 北大核心 2024年第7期1100-1103,共4页
近年甲状腺癌发病率迅速升高,以甲状腺乳头状癌(PTC)最为常见。部分PTC具有高侵袭性,主要表现为早期颈部淋巴结转移(CLNM)、甲状腺外侵犯(ETE)及基因突变等。超声影像组学(USR)及其联合基因检测有助于诊断及评估PTC。本文就USR及其联合... 近年甲状腺癌发病率迅速升高,以甲状腺乳头状癌(PTC)最为常见。部分PTC具有高侵袭性,主要表现为早期颈部淋巴结转移(CLNM)、甲状腺外侵犯(ETE)及基因突变等。超声影像组学(USR)及其联合基因检测有助于诊断及评估PTC。本文就USR及其联合基因检测筛选高侵袭性PTC研究进展进行综述。 展开更多
关键词 甲状腺癌 乳头状 肿瘤转移 基因 超声检查 影像组学
下载PDF
不同浓度碘对甲状腺癌细胞增殖的影响
18
作者 杨筱瑶 王亦薇 +1 位作者 袁颖 张翼鸿 《当代医学》 2024年第4期110-113,共4页
目的探讨不同浓度碘对甲状腺癌细胞增殖的影响。方法采用不同碘浓度培养BCPAP细胞,并分为对照组(不含碘)、高碘浓度组(含碘1.0×10^(-3)mol/L)和适量碘浓度组(含碘1.0×10^(-6)mol/L),检测BCPAP细胞增殖能力;采用高通量测序方... 目的探讨不同浓度碘对甲状腺癌细胞增殖的影响。方法采用不同碘浓度培养BCPAP细胞,并分为对照组(不含碘)、高碘浓度组(含碘1.0×10^(-3)mol/L)和适量碘浓度组(含碘1.0×10^(-6)mol/L),检测BCPAP细胞增殖能力;采用高通量测序方法检测BCPAP细胞RNA,比较不同碘浓度对BCPAP细胞增殖的影响及细胞差异基因的表达情况。结果高碘浓度组BCPAP细胞增殖能力低于对照组和适量碘浓度组,而适量碘浓度组高于对照组,差异有统计学意义(P<0.05)。高碘浓度组与对照组细胞间共有522个差异表达基因,其中上调基因266个,下调基因256个;适量碘浓度组与对照组细胞间共有552个差异表达基因,其中上调基因10个,下调基因542个。结论高浓度碘抑制甲状腺癌细胞增殖起,适量浓度碘可促进甲状腺癌细胞增殖,高碘浓度组和适量碘浓度组皆有差异表达基因。 展开更多
关键词 甲状腺癌细胞 高通量测序 差异表达基因
下载PDF
甲状腺乳头状癌临床及超声特征与中央区淋巴结转移及BRAF V600E基因突变的相关性研究
19
作者 伍小芳 张苗苗 +1 位作者 赵若兰 王影 《肿瘤影像学》 2024年第3期256-262,共7页
目的:探究甲状腺乳头状癌(papillary carcinoma of the thyroid,PTC)患者的临床和超声特征预测中央区淋巴结转移(central lymph node metastasis,CLNM)的价值及其与BRAF V600E基因突变的相关性。方法:选择534例PTC患者进行回顾性研究,... 目的:探究甲状腺乳头状癌(papillary carcinoma of the thyroid,PTC)患者的临床和超声特征预测中央区淋巴结转移(central lymph node metastasis,CLNM)的价值及其与BRAF V600E基因突变的相关性。方法:选择534例PTC患者进行回顾性研究,根据术前超声诊断可疑PTC病灶大小进行分组。收集患者的临床信息及可疑病灶的超声特征,使用多因素分析及分层分析筛选出与CLNM及BRAF V600E基因突变相关的危险因素。结果:多因素及分层分析表明,病灶与被膜紧贴及BRAF V600E基因突变是PTC病灶>10 mm患者发生CLNM的危险因素;病灶存在微钙化、男性是甲状腺微小乳头状癌(papillary thyroid microcarcinoma,PTMC)患者发生CLNM的危险因素(均P<0.05)。BRAF V600E基因突变的发生与桥本甲状腺炎(Hashimoto thyroiditis,HT)的缺失显著相关(P<0.001)。结论:当患者出现可疑的>10 mm PTC病灶且紧贴被膜时,可进行BRAF V600E基因检测预测CLNM的发生。当可疑病灶<10 mm时,男性或病灶存在微钙化的患者更易发生CLNM。病灶较大或无HT共存的PTC患者BRAF V600E基因突变概率更高。PTC的临床和病灶超声特征对CLNM的转移有预测价值,并且与BRAF V600E基因突变相关,有助于临床为患者选择合理的手术方式。 展开更多
关键词 甲状腺乳头状癌 超声 BRAF V600E基因 中央区淋巴结转移
下载PDF
BRAF^(V600E)基因检测对TBSRTCⅠ类、Ⅱ类甲状腺结节良恶性的诊断价值探讨
20
作者 曹丁方 马东林 朴颖实 《中国耳鼻咽喉头颈外科》 CSCD 2024年第10期626-630,共5页
目的探讨BRAFV600E基因检测对TBSRTCⅠ类、Ⅱ类甲状腺结节良恶性的辅助诊断价值。方法回顾性收集首都医科大学附属北京同仁医院2021年8月~2024年6月超声引导下细针穿刺细胞学检查(FNAC)结果为TBSRTCⅠ类和Ⅱ类甲状腺结节同时具有BRAF^(V... 目的探讨BRAFV600E基因检测对TBSRTCⅠ类、Ⅱ类甲状腺结节良恶性的辅助诊断价值。方法回顾性收集首都医科大学附属北京同仁医院2021年8月~2024年6月超声引导下细针穿刺细胞学检查(FNAC)结果为TBSRTCⅠ类和Ⅱ类甲状腺结节同时具有BRAF^(V600E)基因检测结果的病例,其中Ⅰ类176例,182个结节;Ⅱ类492例,503个结节。以有手术组织病理结果做“金标准”的结节为研究对象,包括Ⅰ类26个,Ⅱ类37个,分析BRAF^(V600E)基因检测对TBSRTCⅠ类、Ⅱ类结节良恶性鉴别的灵敏度、特异度、阳性预测值、阴性预测值和准确性。结果26个TBSRTCⅠ类结节中有22个为甲状腺乳头状癌(PTC),4个为良性病变;37个Ⅱ类结节中有18个为PTC,19个为良性病变。BRAF^(V600E)基因检测对TBSRTCⅠ类、Ⅱ类结节良恶性鉴别的灵敏度分别为100%(22/22)、83.3%(15/18),特异度分别为100%(4/4)、94.7%(18/19),阳性预测值分别为100%(22/22)、93.7%(15/16),阴性预测值分别为100%(4/4)、85.7%(18/21),准确性分别为100%(26/26)、89.2%(33/37)。重复穿刺的3个甲状腺结节FNAC结果一致率为0%(0/3),BRAF^(V600E)基因检测结果一致率为100%(1/1)。结论BRAF^(V600E)基因检测对于TBSRTCⅠ类、Ⅱ类甲状腺结节良恶性鉴别是有效的辅助诊断手段,除对TBSRTCⅢ~Ⅴ类结节进行BRAF^(V600E)基因检测之外,TBSRTCⅠ类及Ⅱ类结节也建议纳入常规BRAF^(V600E)基因检测以减少患者重复穿刺的必要及降低对PTC的漏诊率。 展开更多
关键词 甲状腺结节 诊断 BRAF^(V600E)基因检测 细针穿刺细胞学检查
下载PDF
上一页 1 2 50 下一页 到第
使用帮助 返回顶部